SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa

SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa

Data on immune response to the SARS-COV-2 AZD1222 vaccine are limited in African populations. Here, the authors show immunogenicity of the AZD1222 vaccine in two independent cohorts from West Africa, including seroprevalence levels prior to vaccine rollout in January 2021.

Bibliographic Details
Main Authors: Adam Abdullahi, David Oladele, Michael Owusu, Steven A. Kemp, James Ayorinde, Abideen Salako, Douglas Fink, Fehintola Ige, Isabella A. T. M. Ferreira, Bo Meng, Augustina Angelina Sylverken, Chika Onwuamah, Kwame Ofori Boadu, Kazeem Osuolale, James Opoku Frimpong, Rufai Abubakar, Azuka Okuruawe, Haruna Wisso Abdullahi, Gideon Liboro, Lawrence Duah Agyemang, Nana Kwame Ayisi-Boateng, Oluwatosin Odubela, Gregory Ohihoin, Oliver Ezechi, Japhet Senyo Kamasah, Emmanuel Ameyaw, Joshua Arthur, Derrick Boakye Kyei, Dorcas Ohui Owusu, Olagoke Usman, Sunday Mogaji, Adedamola Dada, George Agyei, Soraya Ebrahimi, Lourdes Ceron Gutierrez, Sani H. Aliyu, Rainer Doffinger, Rosemary Audu, Richard Adegbola, Petra Mlcochova, Richard Odame Phillips, Babatunde Lawal Solako, Ravindra K. Gupta
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-33792-x

Internet

https://doi.org/10.1038/s41467-022-33792-x

Similar Items